Semaglutide
A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with an extended half-life that supports once-weekly administration. Originally developed for type 2 diabetes, it is now one of the most widely studied peptides in metabolic and weight-management research.
Benefits
- Reduces appetite and food intake via central pathways
- Slows gastric emptying for prolonged satiety
- Improves glycemic control and insulin sensitivity
- Demonstrated significant weight reduction in clinical trials
Mechanism of Action
Semaglutide binds to GLP-1 receptors throughout the body, with key activity in the pancreas, hypothalamus, and gastrointestinal tract. It enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric motility, and signals satiety in appetite-regulating brain regions.
Dosage (informational only)
- Typical range
- 0.25–2.4 mg per week
- Frequency
- Weekly subcutaneous administration
Dosing is typically titrated upward over several weeks to minimize gastrointestinal side effects. Always consult a qualified clinician.
Side Effects
- Nausea, particularly during titration
- Constipation or diarrhea
- Fatigue or headache
- Rare reports of pancreatitis or gallbladder issues
Related peptides
A dual GIP and GLP-1 receptor agonist with strong effects on appetite, glucose handling, and body composition.
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing some of the largest weight-loss results recorded in trials.
A small-molecule oral GLP-1 receptor agonist studied as a needle-free alternative to injectable incretin therapy.